The efficacy of levetiracetam for focal seizures and its blood levels in children

Brain and Development

Volumn 37, Issue 8, 2015, Pages 773-779

  Iwasaki, Toshiyuki ^a   Toki, Taira ^a   Nonoda, Yutaka ^a   Ishii, Masahiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiepileptic drug; Maintenance dosage; Optimal range; Seizure reduction rate; Side effect

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; TOPIRAMATE; ZONISAMIDE; ANTICONVULSIVE AGENT; PIRACETAM;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; AWARENESS; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; INFANT; JAPANESE (PEOPLE); LONG TERM CARE; MAINTENANCE DRUG DOSE; MALE; RISK REDUCTION; SCHOOL CHILD; SEIZURE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; NEWBORN; PRESCHOOL CHILD; PROSPECTIVE STUDY; SEIZURES; TREATMENT OUTCOME;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; PIRACETAM; PROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME;

EID: 84939271012     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2014.11.008     Document Type: Article

References (26)

1. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 2001, 42(Suppl 4):S13-S18.
2. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
3. May T.W., Rambeck B., Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003, 25:690-699.
4. Welty T.E., Gidal B.E., Ficker D.M., Privitera M.D. Levetiracetam: a different approach to the pharmacotherapy of epilepsy. Ann Pharmacother 2002, 36:296-304.
5. Giroux P.C., Salas-Prato M., Théorêt Y., Carmant L. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy. Seizure 2009, 18:559-563.
6. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001, 15:405-417.
7. Tomson T. Drug selection for the newly diagnosed patient: when is a new generation antiepileptic drug indicated?. J Neurol 2004, 251:1043-1049.
8. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006, 61:246-255.
9. Wheless J.W. Levetiracetam in the treatment of childhood epilepsy. Neuropsychiatr Dis Treat 2007, 3:409-421.
10. Verrotti A., D'Adamo E., Parisi P., Chiarelli F., Curatolo P. Levetiracetam in childhood epilepsy. Pediatr Drugs 2010, 12:177-186.
11. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000, 85:77-85.
12. Pellock J.M., Glauser T.A., Bebin E.M., Fountain N.B., Ritter F.J., Coupez R.M., et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001, 42:1574-1579.
13. von Stuelpnagel C., Holthausen H., Kluger G. Long-term use of levetiracetam in patients with severe childhood-onset epilepsy. Eur J Paediatr Neurol 2007, 11:341-345.
14. Kanemura H., Sano F., Tando T., Sugita K., Aihara M. Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy. Brain Dev 2013, 35:386-391.
15. French J., Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005, 46:324-326.
16. Lancelin F., Franchon E., Kraoul L., Garciau I., Brovedani S., Tabaouti K., et al. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther Drug Monit 2007, 29:576-583.
17. Glauser T.A., Mitchell W.G., Weinstock A., Bebin M., Chen D., Coupez R., et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 2007, 48:1117-1122.
18. Fountain N.B., Conry J.A., Rodríguez-Leyva I., Gutierrez-Moctezuma J., Salas E., Coupez R., et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res 2007, 74:60-69.
19. Boon P., Chauvel P., Pohlmann-Eden B., Otoul C., Wroe S. Dose-response effect of levetiracetam 1000 and 2000mg/day in partial epilepsy. Epilepsy Res 2002, 48:77-89.
20. Meencke H.J., Buyle S. Assessment of a dose-response relationship of levetiracetam. Eur J Neurol 2006, 13:942-946.
21. Nonoda Y., Iwasaki T., Ishii M. The efficacy of gabapentin in children of partial seizures and the blood levels. Brain Dev 2014, 36:194-202.
22. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., et al. N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006, 66:1654-1660.
23. Food and Drug Administration [Internet]. Silver Spring: NDA 21035/S-089 & NDA 21505/S-030 Keppra tablet and oral solution FDA Approved Labeling text dated Jul 2013. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
24. Gower A.J., Noyer M., Verloes R., Gobert J., Wülfert E. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992, 222:193-203.
25. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000, 55:236-242.
26. Ben-Menachem E., Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000, 41:1276-1283.